Outcomes of Patients With Inflammatory Bowel Diseases Switched from Maintenance Therapy with a Biosimilar to Remicade.

Outcomes of Patients With Inflammatory Bowel Diseases Switched from Maintenance Therapy with a Biosimilar to Remicade. Clin Gastroenterol Hepatol. 2019 Jan 07;: Authors: Ilias A, Szanto K, Gonczi L, Kurti Z, Golovics PA, Farkas K, Schafer E, Szepes Z, Szalay B, Vincze A, Szamosi T, Molnar T, Lakatos PL Abstract BACKGROUND & AIMS: There is evidence that it is safe and effective for patients with inflammatory bowel diseases (IBD) to switch from maintenance therapy with an original infliximab drug to a biosimilar, but little is known about outcomes of reverse…

Read More

Infliximab Exposure-Response Relationship and Thresholds Associated with Endoscopic Healing in Patients With Ulcerative Colitis.

Related Articles Infliximab Exposure-Response Relationship and Thresholds Associated with Endoscopic Healing in Patients With Ulcerative Colitis. Clin Gastroenterol Hepatol. 2018 Oct 26;: Authors: Vande Casteele N, Jeyarajah J, Jairath V, Feagan BG, Sandborn WJ Abstract BACKGROUND & AIMS: Therapeutic drug monitoring might be used to personalize infliximab treatment of patients with ulcerative colitis (UC), although exposure thresholds associated with endoscopic healing are uncertain. We aimed to determine infliximab concentration thresholds associated with endoscopic outcomes during induction and maintenance therapy for patients with UC. METHODS: We analyzed data from 484 patients…

Read More

Predictors of relapse following infliximab de-escalation in patients with inflammatory bowel disease: the value of a strategy based on therapeutic drug monitoring.

Predictors of relapse following infliximab de-escalation in patients with inflammatory bowel disease: the value of a strategy based on therapeutic drug monitoring. Aliment Pharmacol Ther. 2019 Jan;49(2):147-154 Authors: Lucidarme C, Petitcollin A, Brochard C, Siproudhis L, Dewitte M, Landemaine A, Bellissant E, Bouguen G Abstract BACKGROUND: There are limited data concerning infliximab drug monitoring during de-escalation of the treatment of inflammatory bowel disease (IBD). AIM: To define the rate and the predictors of relapse following infliximab de-escalation in IBD patients in remission. METHODS: All IBD patients at a single referral…

Read More

Systematic Review: Efficacy and Safety of Accelerated Induction Regimes in Infliximab Rescue Therapy for Hospitalized Patients with Acute Severe Colitis.

Related Articles Systematic Review: Efficacy and Safety of Accelerated Induction Regimes in Infliximab Rescue Therapy for Hospitalized Patients with Acute Severe Colitis. Dig Dis Sci. 2018 Dec 07;: Authors: Sebastian S, Myers S, Nadir S, Subramanian S Abstract BACKGROUND: Pharmacokinetic data suggest that standard induction dosing schedules may not be sufficient in patients with acute severe colitis (ASUC). Hence, intensified induction regimes are increasingly used in the rescue treatment of hospitalized patients with ASUC to avoid the need for colectomy although the evidence for this is uncertain. AIM: To conduct…

Read More

Loss of efficacy and safety of the switch from infliximab original to infliximab biosimilar (CT-P13) in patients with inflammatory bowel disease.

Related Articles Loss of efficacy and safety of the switch from infliximab original to infliximab biosimilar (CT-P13) in patients with inflammatory bowel disease. World J Gastroenterol. 2018 Dec 14;24(46):5288-5296 Authors: Guerra Veloz MF, Argüelles-Arias F, Castro Laria L, Maldonado Pérez B, Benítez Roldan A, Perea Amarillo R, Merino Bohórquez V, Calleja MA, Caunedo Álvarez Á, Vilches Arenas Á Abstract BACKGROUND: Infliximab original has changed the natural history of inflammatory bowel diseases (IBD) over the past two decades. However, the recent expiration of its patent has allowed the entry of the…

Read More

Therapeutic Drug Monitoring is More Cost-Effective than a Clinically Based Approach in the Management of Loss of Response to Infliximab in Inflammatory Bowel Disease: An Observational Multicentre Study.

Related Articles Therapeutic Drug Monitoring is More Cost-Effective than a Clinically Based Approach in the Management of Loss of Response to Infliximab in Inflammatory Bowel Disease: An Observational Multicentre Study. J Crohns Colitis. 2018 Dec 11;: Authors: Yanai H, Dotan I PMID: 30535008 [PubMed – as supplied by publisher] PubMed Link: https://www.ncbi.nlm.nih.gov/pubmed/30535008?dopt=Abstract

Read More

Infliximab Trough Levels Are Associated With Mucosal Healing During Maintenance Treatment With Infliximab in Paediatric Crohn’s Disease.

Infliximab Trough Levels Are Associated With Mucosal Healing During Maintenance Treatment With Infliximab in Paediatric Crohn’s Disease. J Crohns Colitis. 2018 Nov 19;: Authors: Kang B, Choi SY, Choi YO, Lee SY, Baek SY, Sohn I, Choe BH, Lee HJ, Choe YH Abstract Background and Aims: Mucosal healing is an important treatment goal in Crohn’s disease. We investigated the association between serum infliximab trough levels and mucosal healing, and the infliximab cut-off levels required for mucosal healing in paediatric patients. Methods: In this multicentre, retrospective, cross-sectional study, medical records and…

Read More

High-Dose Infliximab Rescue Therapy for Hospitalized Acute Severe Ulcerative Colitis Does Not Improve Colectomy-Free Survival.

Related Articles High-Dose Infliximab Rescue Therapy for Hospitalized Acute Severe Ulcerative Colitis Does Not Improve Colectomy-Free Survival. Dig Dis Sci. 2018 Nov 16;: Authors: Chao CY, Khoury AA, Aruljothy A, Restellini S, Wyse J, Afif W, Bitton A, Lakatos PL, Bessissow T Abstract BACKGROUND AND OBJECTIVE: Optimization strategies with infliximab (IFX) are increasingly used as rescue therapy for steroid refractory acute severe ulcerative colitis (ASUC). We aim to determine if intensified IFX induction improves colectomy rate and identifies outcome predictors. METHODS: Hospitalized adult patients who received IFX for ASUC between…

Read More

Systematic review: efficacy and safety of switching patients between reference and biosimilar infliximab.

Related Articles Systematic review: efficacy and safety of switching patients between reference and biosimilar infliximab. Aliment Pharmacol Ther. 2018 Nov 08;: Authors: Feagan BG, Lam G, Ma C, Lichtenstein GR Abstract BACKGROUND: Biosimilar versions of widely prescribed drugs, including the tumour-necrosis factor antagonist infliximab, are becoming increasingly available. As biosimilars are not identical copies of reference products, evidence may be required to demonstrate that switching between a reference biologic and biosimilars is safe and efficacious. To establish interchangeability, US Food and Drug Administration guidance states that studies must demonstrate that…

Read More

Trick or TREAT? More Safety Data of Infliximab During Pregnancy.

Related Articles Trick or TREAT? More Safety Data of Infliximab During Pregnancy. Am J Gastroenterol. 2018 Oct 17;: Authors: Kane S Abstract Infliximab was the first FDA approved biologic for the treatment of Crohn’s disease. Data for its use before and during pregnancy in both females and males have been increasing over the last decade, but most studies have had fewer than 100 patients and inconsistent comparison to healthy control outcomes. New data from the TREAT Safety Registry have a robust N of female and male patients exposed to infliximab…

Read More
<< Go Back